Drugs / TL117
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04843098 | May 2021 → Nov 2024 overdue | head and neck squamous cell carcinoma | Suzhou Junde Biotechnology Co., Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TL117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04843098 ↗ |
| Action | Inhibit | “PI3K Inhibitor TL117” NCT04843098 ↗ |
| Route | Oral | “TL117 capsules orally once daily” NCT04843098 ↗ |